Outcomes After Anti-PD-1 Therapy Discontinuation in Melanoma

The introduction of immune checkpoint inhibitors such as anti-PD-1 monoclonal antibodies radically altered the treatment paradigm for advanced melanoma, from a disease with limited treatment options and short survival to one in which durable responses and long-term survival can be achieved. While PD-1 inhibitors have become an essential component of melanoma treatment, little is known […]

Read More

Pembrolizumab Consolidation Active in Hodgkin Lymphoma Posttransplant

For patients with relapsed/refractory classical Hodgkin lymphoma who responded to salvage chemotherapy, autologous stem cell transplant (ASCT) remains the gold standard of treatment. While this may result in cure for some patients, up to half will relapse, and treatments following relapse are associated with short survival. However, results from a phase III AETHERA study demonstrated […]

Read More

ALK Resistance Mutations May Predict Efficacy of Lorlatinib in NSCLC

Treatment of patients with advanced non-small cell lung cancer (NSCLC) who harbor anaplastic lymphoma kinase (ALK) gene rearrangements is rapidly evolving and includes different ALK-targeting tyrosine kinase inhibitors (TKIs). Currently five ALK TKIs are approved by the FDA, including the first-generation TKI crizotinib, the second-generation TKIs alectinib, brigatinib, and ceritinib, and the third generation lorlatinib. […]

Read More

Preoperative ctDNA Predictive for Survival in Stage III Melanoma

Patients with stage III melanoma who are at high risk of recurrence, such as those with lymph node involvement, typically undergo complete surgical resection followed by adjuvant-targeted therapy (BRAF V600 mutant) or immunotherapy. However, current strategies for estimating risk of recurrence are flawed, and it is difficult to accurately identify those patients for whom the […]

Read More

Pembrolizumab Effective for Platinum-Refractory Cervical Cancer

Patients with advanced cervical cancer face a poor prognosis. Paclitaxel and cisplatin combined with bevacizumab is the recommended first-line treatment regimen for patients with recurrent or metastatic cervical cancer. Treatment for patients progressing following first-line therapy is a high, unmet need.  Single-agent chemotherapies are commonly used in this setting, but response rates are low and […]

Read More

M371 Test Useful as a New Biomarker in Testicular Germ Cell Tumors

Testing for α-fetoprotein (AFP), β-human chorionic gonadotropin (β-HCG), and lactate dehydrogenase (LDH) in blood is essential for diagnosis, staging, and monitoring of testicular germ cell tumors (GCTs). Unfortunately, these biomarkers have low overall sensitivity and are inconsistently expressed across different GCT subtypes. Several small studies have demonstrated that serum levels of microRNA (miRNA)-371a-3p (commonly called […]

Read More

Lenvatinib Plus Pembrolizumab Promising in Advanced Endometrial Cancer

Treatment options for patients with advanced endometrial cancer are limited and chemotherapy, which is the current standard, is associated with low response rates and poor  outcome. While immunotherapy with PD-1 and PD-L1 inhibitors has been highly effective in patients with high microsatellite instability (MSI-H), the majority of advanced endometrial cancers are microsatellite stable (MSS), and […]

Read More

Neratinib Combo Effective in HER2+ Breast Cancer Brain Metastases

Despite expanded targeted treatment options for human epidermal growth factor receptor 2 (HER2)-positive breast cancer, nearly half of patients with metastatic disease develop central nervous system (CNS) metastases, which are a source of major morbidity and mortality for the majority of patients. Evidence-supported therapies for these patients are limited, and treatment of CNS progression remains […]

Read More

Increased Toxicity When PD-(L)1 Inhibitor Is Followed by Osimertinib

The treatment landscape for advanced non-small cell lung cancer (NSCLC) is constantly changing. Osimertinib, a third-generation EGFR tyrosine kinase inhibitor, is standard of care for EGFR-mutant NSCLC, and the indications for PD-(L)1 targeting immune checkpoint inhibitors are rapidly expanding and include metastatic (first-line and beyond) and locally advanced disease. With the introduction of multiple novel […]

Read More

Pertuzumab and Trastuzumab Combo Active For HER2-Positive mCRC

For patients with HER2-overexpressed or -amplified breast or gastric cancer, treatment with HER2-targeting agents is standard of care.  HER2 amplification/overexpression in metastatic colorectal cancer (mCRC) is rare (approximately 2% to 6% of patients). This low frequency of HER2 alterations has constrained investigations of HER2-targeted therapies in mCRC. However, based on the activity of HER2-targeted combinations […]

Read More